Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Sep 17, 2020 (6 years ago)

NP Thyroid 15 (Levothyroxine, Liothyronine)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

NP Thyroid 15,Thyroid Tablets, USP 1/4 grain (15 mg) 100-count bottles, Rx Only, Manufactured For: Acella Pharmaceuticals, LLC Alpharetta, GA 30005, NDC 42192-327-01

Affected NDC 42192-0327-01

Compare with the code on your package — it is the most precise check available.

Drug: Thyroid Category: Thyroid Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
NP Thyroid 15
Levothyroxine, Liothyronine
NDC 42192-0327
LIOTHYRONINE 2.25 ug/1; LEVOTHYROXINE 9.5 ug/1 Tablet
Oral
Acella Pharmaceuticals, LLC Rx
Recalling firm
Acella Pharmaceuticals, LLC
NDC code
42192-327-01
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0035-2021 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Thyroid recalls

See all
Class II · Moderate risk

Thyroid

Subpotent Drug

Ongoing Wrong potency / content Specialty Process Labs LLC NDC 81305-100-02 D-0294-2026
Class II · Moderate risk

S.P Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC D-0447-2024
Class II · Moderate risk

S.P.Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC NDC 81305-500-01 D-0446-2024

Other recalls by Acella Pharmaceuticals, LLC

All 2020 recalls
Class II · Moderate risk

Naproxen Oral Suspension

Chemical contamination; presence of lead and lithium above specification

Ongoing Chemical / undeclared Acella Pharmaceuticals, LLC NDC 42192-619-16 D-0523-2026
Class II · Moderate risk

Doxycycline Hyclate Tablets

Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications.

Ongoing Dissolution failure Acella Pharmaceuticals, LLC NDC 42192-501-05 D-0014-2026